Business Wire·Oct 1, 2026, 8:00 AM ET

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon will present real-world effectiveness data for VTAMA (tapinarof) 1% cream in atopic dermatitis patients at the 2026 Fall Clinical Dermatology Conference in Las Vegas.
The analysis evaluates improvements in physician-reported outcomes, including body surface area & physician's global assessment, alongside patient-reported itch scores.
VTAMA is indicated as an aryl hydrocarbon receptor agonist for topical treatment of plaque psoriasis in adults & atopic dermatitis in adults & pediatric patients aged 2 years & older.
Common adverse reactions in plaque psoriasis patients (incidence ≥1%) include folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, & influenza.
Common adverse reactions in atopic dermatitis patients (incidence ≥1%) include upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, & abdominal pain.
Organon is a global healthcare company headquartered in Jersey City, New Jersey, with a portfolio of over 70 products across Women's Health & General Medicines.
The press release includes forward-looking statements regarding the planned data presentation & future dissemination of clinical data subject to risks & uncertainties.